We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MDT Stock May Gain From FDA's Nod for Stealth AXiS Surgical System
Read MoreHide Full Article
Key Takeaways
MDT secured FDA approval for Stealth AXiS in cranial and ENT, adding to the February spine clearance.
MDT's AI-enabled system unifies planning, navigation and robotics with tractography and real-time ultrasound.
MDT gains from rising MIS demand as the surgical robotics market is set to grow at a 7.3% CAGR through 2032.
Medtronic plc (MDT - Free Report) recently announced that it has secured the FDA’s approval for the Stealth AXiS surgical system for cranial and ear, nose and throat (ENT) procedures. Following clearance for spine procedures in February, the Stealth AXiS surgical system unifies surgical planning, navigation and robotics into a single intelligent system to support surgeons with greater precision and real-time insights during complex procedures.
The latest development reinforces Medtronic's strategy to deliver connected technologies that support surgeons across multiple specialties on a single platform. The approval is also expected to bolster its Neuroscience portfolio.
MDT Stock’s Likely Trend Following the News
Since the March 27 announcement, MDT shares have dipped 0.6%, closing yesterday’s session at $86.65. On a promising note, Medtronic boasts one of the broadest pipelines in Neuroscience, with Cranial and Spinal Technologies continuing to be a steady contributor. The business spans a portfolio of 150 products covering more than 20 pathologies, addressing the complex challenges faced by spine and neurosurgeons.
Through its ENT business, the company delivers innovative technologies that impact nearly 3 million patients each year. Building on 25 years of navigation leadership, the Stealth AXiS surgical system creates a powerful platform for the next generation of ENT innovation. We expect the news to help drive a rebound in MDT stock price.
Medtronic has a market capitalization of $118.08 billion at present. Going by the Zacks Consensus Estimate, the company’s fiscal 2026 earnings per share (EPS) are expected to grow 2.4% over 2025. It has delivered an earnings beat of 2.76%, on average, in the trailing four quarters.
More on MDT’s Newest Platform
The platform’s standout capability is its AI-enabled architecture, which supports advanced planning and visualization before, during and after surgery. For cranial procedures, the Stealth AXiS surgical system includes AI-based automatic tractography that helps surgeons generate patient-specific brain maps and visualize critical neural pathways associated with essential brain functions. It also integrates intraoperative ultrasound through GE HealthCare's bkActiv, providing additional real-time imaging during procedures.
Image Source: Zacks Investment Research
For ENT procedures, the system provides high-precision navigation and advanced visualization designed for the intricate anatomy of the sinuses and skull base. Built around real-world ENT workflows, the system offers sharper anatomical detail and faster responsiveness to support confident decision-making in the operating room (OR), along with intuitive, surgeon-centered workflows to create a familiar user experience while delivering enhanced capabilities.
The system's flexible architecture is also designed to support continuous software innovation, expanded capabilities and deeper ecosystem connectivity to help shape the next era of surgery.
Industry Prospects Favoring MDT
According to Data Bridge Market Research, the global surgical robotics and navigation market was valued at $3.52 billion in 2024 and is projected to expand at a CAGR of 7.3% through 2032. Demand for these systems is mainly driven by the growing preference for minimally invasive surgeries (MIS), which offer advantages such as smaller incisions, reduced risk of complications, shorter hospital stays and quicker recovery times.
Globally, these are also ranked among the most critical tools in modern ORs, especially for high-precision and complex surgeries.
Medtronic’s Other Developments
This month, the company has entered into an exclusive distribution agreement with Merit Medical Systems, Inc. to offer FDA-cleared ViaVerte — a minimally invasive and implant-free basivertebral nerve ablation (BVNA) system. Merit Medical currently supplies Medtronic's Kyphon Xpander Inflation Syringes used in balloon kyphoplasty procedures and Kyphon KyphoFlex unipedicular steerable balloon catheter for treating vertebral compression fractures.
MDT Stock Price Performance
Over the past year, MDT stock has plunged 2.5% compared with the industry’s 23.4% fall.
MDT’s Zacks Rank and Top Picks
Medtronic currently carries a Zacks Rank #3 (Hold).
Estimates for Envista’s 2026 EPS have increased 11.9% in the past 60 days. Shares of the company have surged 44.9% in the past year against the industry’s 23.4% decline. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.4%. In the last reported quarter, it delivered an earnings surprise of 18.8%.
Globus Medical shares have risen 14% in the past year. Estimates for the company’s 2026 EPS have increased 11.2% to $4.46 in the past 30 days. GMED’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 18.8%. In the last reported quarter, it posted an earnings surprise of 20.8%.
BrightSpring Health Services shares have soared 134.5% in the past year. Estimates for the company’s 2026 EPS have jumped 20.1% to $1.61 in the past 30 days. BTSG’s earnings topped estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 40.4%. It has an estimated long-term earnings growth rate of 47.2% compared with the industry’s 14.5% growth.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
MDT Stock May Gain From FDA's Nod for Stealth AXiS Surgical System
Key Takeaways
Medtronic plc (MDT - Free Report) recently announced that it has secured the FDA’s approval for the Stealth AXiS surgical system for cranial and ear, nose and throat (ENT) procedures. Following clearance for spine procedures in February, the Stealth AXiS surgical system unifies surgical planning, navigation and robotics into a single intelligent system to support surgeons with greater precision and real-time insights during complex procedures.
The latest development reinforces Medtronic's strategy to deliver connected technologies that support surgeons across multiple specialties on a single platform. The approval is also expected to bolster its Neuroscience portfolio.
MDT Stock’s Likely Trend Following the News
Since the March 27 announcement, MDT shares have dipped 0.6%, closing yesterday’s session at $86.65. On a promising note, Medtronic boasts one of the broadest pipelines in Neuroscience, with Cranial and Spinal Technologies continuing to be a steady contributor. The business spans a portfolio of 150 products covering more than 20 pathologies, addressing the complex challenges faced by spine and neurosurgeons.
Through its ENT business, the company delivers innovative technologies that impact nearly 3 million patients each year. Building on 25 years of navigation leadership, the Stealth AXiS surgical system creates a powerful platform for the next generation of ENT innovation. We expect the news to help drive a rebound in MDT stock price.
Medtronic has a market capitalization of $118.08 billion at present. Going by the Zacks Consensus Estimate, the company’s fiscal 2026 earnings per share (EPS) are expected to grow 2.4% over 2025. It has delivered an earnings beat of 2.76%, on average, in the trailing four quarters.
More on MDT’s Newest Platform
The platform’s standout capability is its AI-enabled architecture, which supports advanced planning and visualization before, during and after surgery. For cranial procedures, the Stealth AXiS surgical system includes AI-based automatic tractography that helps surgeons generate patient-specific brain maps and visualize critical neural pathways associated with essential brain functions. It also integrates intraoperative ultrasound through GE HealthCare's bkActiv, providing additional real-time imaging during procedures.
Image Source: Zacks Investment Research
For ENT procedures, the system provides high-precision navigation and advanced visualization designed for the intricate anatomy of the sinuses and skull base. Built around real-world ENT workflows, the system offers sharper anatomical detail and faster responsiveness to support confident decision-making in the operating room (OR), along with intuitive, surgeon-centered workflows to create a familiar user experience while delivering enhanced capabilities.
The system's flexible architecture is also designed to support continuous software innovation, expanded capabilities and deeper ecosystem connectivity to help shape the next era of surgery.
Industry Prospects Favoring MDT
According to Data Bridge Market Research, the global surgical robotics and navigation market was valued at $3.52 billion in 2024 and is projected to expand at a CAGR of 7.3% through 2032. Demand for these systems is mainly driven by the growing preference for minimally invasive surgeries (MIS), which offer advantages such as smaller incisions, reduced risk of complications, shorter hospital stays and quicker recovery times.
Globally, these are also ranked among the most critical tools in modern ORs, especially for high-precision and complex surgeries.
Medtronic’s Other Developments
This month, the company has entered into an exclusive distribution agreement with Merit Medical Systems, Inc. to offer FDA-cleared ViaVerte — a minimally invasive and implant-free basivertebral nerve ablation (BVNA) system. Merit Medical currently supplies Medtronic's Kyphon Xpander Inflation Syringes used in balloon kyphoplasty procedures and Kyphon KyphoFlex unipedicular steerable balloon catheter for treating vertebral compression fractures.
MDT Stock Price Performance
Over the past year, MDT stock has plunged 2.5% compared with the industry’s 23.4% fall.
MDT’s Zacks Rank and Top Picks
Medtronic currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Envista (NVST - Free Report) , Globus Medical (GMED - Free Report) and BrightSpring Health Services (BTSG - Free Report) . Each of these sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Envista’s 2026 EPS have increased 11.9% in the past 60 days. Shares of the company have surged 44.9% in the past year against the industry’s 23.4% decline. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.4%. In the last reported quarter, it delivered an earnings surprise of 18.8%.
Globus Medical shares have risen 14% in the past year. Estimates for the company’s 2026 EPS have increased 11.2% to $4.46 in the past 30 days. GMED’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 18.8%. In the last reported quarter, it posted an earnings surprise of 20.8%.
BrightSpring Health Services shares have soared 134.5% in the past year. Estimates for the company’s 2026 EPS have jumped 20.1% to $1.61 in the past 30 days. BTSG’s earnings topped estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 40.4%. It has an estimated long-term earnings growth rate of 47.2% compared with the industry’s 14.5% growth.